BIX 2022 – Opening Doors to Korea’s Biopharmaceutical Industry

BIOPLUS-INTERPHEX KOREA (BIX) will be held from August 3-5 at COEX, Seoul. Themed K-BIO Value Chain, the event encompasses biopharmaceutical value chains, including R&D, manufacturing process, logistics, packaging, CMO/CDMO, AI, and big data. Organizers BIOPLUS of KoreaBIO and INTERPHEX are expecting over 10,000 international participants and more than 200 companies to attend and connect with global business networks.

The three-day in-person conference will feature speakers from around the world, keynote and corporate presentations, exhibitions, themed pavilions, and partnering sessions, in particular, over 100 speakers will be featured in sessions covering corporate management, technicals, and latest technologies.

Keynotes on KBIO and CRISP’s Future

Director Hyun Sil Ahn from the AI Economy Institute will chair the K-BIO’s Now and Tomorrow session on the first day, with experts from the biopharmaceutical sector to highlight the invaluable lessons learned from Korea’s rapid developments and how to harvest and develop them for the future.

Speakers include:

• Mahn Soon Hwang, CEO of Korea Investment Partners
• James Lee, CEO of Bridge Biotherapeutics
• Youn Hee Choi, Senior Research Fellow of Korea Institute for Industrial Economics & Trade (KIET)

On August 5, The future of CRISPR Technology keynote will feature Dr. Virginijus Siksnys’ introduction on miniature nucleases that may overcome delivery problems using AAV vectors, and how these tools provide a future platform for genome manipulations. As chief scientist at the Vilnius University Institute of Biotechnology, Dr. Siksnys will leverage his experience with the CRISPR-Cas system to show how systematic exploration of novel Cas9 orthologs can address the current issues faced by genome editing applications.

Themed Exhibitions and Special Pavilions 

200 international and domestic companies will showcase their innovations at COEX Hall A, highlighted by the individual pavilions highlighting CMO/CDMO, Digital Healthcare, Cold Chain Logistics, and Materials, Components and Equipment. The exhibitions will be a great way to discover opportunities to expand businesses to and from Korea, especially in the field of biopharmaceuticals, biotechnology, device development, and manufacturing.

BIOPLUS-INTERPHEX KOREA’s newly introduced partnering program also provides efficient solutions for businesses to connect with Global RX Group’s exhibitors, and enjoy accurate global market trends and opportunities to expand overseas listing, investment, and business beyond Korea.

GeneOnline will exhibit at BIOPLUS-INTERPHEX KOREA 2022, please visit us at booth K16 for the latest biopharma opportunities and stay tuned for the latest coverage from Korea.

Register for BIOPLUS-INTERPHEX KOREA 2022 at https://bit.ly/3NYI19b 

Author

GeneOnline

Related Post

Trials & Approvals

South Korea Puts Everest Medicines’ Nefecon On Fast Track

2023-02-10

Special

Will Biden’s Biomanufacturing Initiative Kill Korean Partnership?

2022-10-12

Special

Scaling up Korea’s Biotech Presence in The Global Value Chain, an Interview with Seung Kyou Lee, Vice President of KoreaBIO

2022-08-31